Integrated Investment Consultants LLC Boosts Position in Bristol-Myers Squibb (NYSE:BMY)

Integrated Investment Consultants LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 352,410 shares of the biopharmaceutical company's stock after purchasing an additional 14,292 shares during the quarter. Bristol-Myers Squibb comprises approximately 0.4% of Integrated Investment Consultants LLC's holdings, making the stock its 14th largest position. Integrated Investment Consultants LLC's holdings in Bristol-Myers Squibb were worth $19,932,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. State Street Corp grew its holdings in shares of Bristol-Myers Squibb by 1.6% during the third quarter. State Street Corp now owns 92,896,580 shares of the biopharmaceutical company's stock valued at $4,806,469,000 after buying an additional 1,451,214 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Bristol-Myers Squibb by 3.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 61,030,403 shares of the biopharmaceutical company's stock valued at $3,157,713,000 after purchasing an additional 1,968,729 shares during the last quarter. FMR LLC increased its holdings in shares of Bristol-Myers Squibb by 10.5% in the 3rd quarter. FMR LLC now owns 44,940,609 shares of the biopharmaceutical company's stock worth $2,325,227,000 after purchasing an additional 4,275,787 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 2.5% in the third quarter. Geode Capital Management LLC now owns 43,204,016 shares of the biopharmaceutical company's stock worth $2,228,425,000 after purchasing an additional 1,036,495 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Bristol-Myers Squibb by 3.8% during the second quarter. Legal & General Group Plc now owns 20,225,040 shares of the biopharmaceutical company's stock valued at $839,946,000 after purchasing an additional 735,613 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BMY. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their target price for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Cantor Fitzgerald restated a "neutral" rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Bank of America reiterated a "neutral" rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wolfe Research started coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a "peer perform" rating for the company. Finally, Leerink Partners upgraded Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $56.27.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 1,830 shares of the company's stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company's stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Trading Down 0.0 %

NYSE:BMY traded down $0.03 during mid-day trading on Friday, hitting $56.35. 10,909,530 shares of the stock traded hands, compared to its average volume of 10,195,547. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The stock has a market capitalization of $114.30 billion, a price-to-earnings ratio of -15.70, a PEG ratio of 1.95 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The firm's 50 day moving average is $57.53 and its two-hundred day moving average is $52.00.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $2.00 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.40%. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.